The Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development, (ii) research on and development of research tools and other devices and technologies, and (iii) research to promote strategic initiatives. The 2011 BARDA Strategic Plan defines BARDA's vision and lays out a series of capability goals over a five year period (2011-2016). Amongst BARDA's guiding principles is supporting the development of novel platform technologies that provide flexible systems for the production of medical countermeasures against a variety of threats. Through this Broad Agency Announcement (BAA), BARDA seeks to address, in part, BARDA's Goal 4, responsive and nimble programs and capabilities to address novel and emerging threats, as well as support the technological and scientific advancements of medical countermeasures for biodefense and pandemic influenza. The PAHPA and BARDA Strategic Plan are located on the ASPR website: http://www.phe.gov/Preparedness/legal/pahpa/pages/default.aspx and http://www.phe.gov/about/barda/Pages/2011barda-stratplan.aspx.
This Broad Agency Announcement (BAA) is a continuation of a previous BAA (BARDA-BAA-11-100-SOL-00001) and is similarly designed to promote science and technology advancements of platforms applied to MCM development for the Strategic Science and Technology Division (SST) of BARDA.
The Government's intent is to solicit potential advancements in science and technology in the following BARDA SST Areas of Interest:
1.Pipeline acceleration and evaluation of candidate vaccines and therapeutics.
2.Product improvements to enhance safety, efficacy, ease of use, and manufacturability of MCM.
3.Product repurposing to treat novel and emerging pathogens.
4.In vitro diagnostic platforms for the rapid diagnosis of human infection.
The specific application of the technologies will focus on biodefense, pandemic influenza, and other emerging infectious diseases (EID). BARDA is open to evaluation of technologies at multiple stages of development, but advanced development activities of products specific for CBRN and Influenza will not be considered. Development activities are to be fully integrated with regulatory activities associated with product development efforts.
BARDA anticipates awarding multiple contracts and/or other transactions for research and development efforts from this BAA that have sufficient potential for success, are of interest to the Government, and support one or more of the listed BARDA SST Areas of Interest.
Contact Information:
Comments to this announcement, referencing synopsis BARDA-BAA-12-100-SOL-00013 may be submitted to [email protected].
Contracting Office Address:
Office of the Assistant Secretary for Preparedness & Response (ASPR)
Department of Health and Human Services
330 Independence Ave. SW
G640
Washington, District of Columbia 20201
United States
Please contact the Contracting Officer for additional information.
Point of Contact(s):
Elizabeth Steiner, Contracting Officer
Phone: 202-205-8926
Fax: 202-205-4520
Email: [email protected]
Nathaniel Cohen, Contract Specialist
Phone: 202-205-8968
Fax: 202-205-4520
Email: [email protected]